IL166149A0 - Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity - Google Patents

Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity

Info

Publication number
IL166149A0
IL166149A0 IL16614905A IL16614905A IL166149A0 IL 166149 A0 IL166149 A0 IL 166149A0 IL 16614905 A IL16614905 A IL 16614905A IL 16614905 A IL16614905 A IL 16614905A IL 166149 A0 IL166149 A0 IL 166149A0
Authority
IL
Israel
Prior art keywords
amiodarone
ezetimibe
protection against
against beta
amyloid neurotoxicity
Prior art date
Application number
IL16614905A
Original Assignee
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service filed Critical Hadasit Med Res Service
Priority to IL16614905A priority Critical patent/IL166149A0/en
Priority to PCT/IL2006/000027 priority patent/WO2006072957A1/en
Publication of IL166149A0 publication Critical patent/IL166149A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
IL16614905A 2005-01-05 2005-01-05 Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity IL166149A0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL16614905A IL166149A0 (en) 2005-01-05 2005-01-05 Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity
PCT/IL2006/000027 WO2006072957A1 (en) 2005-01-05 2006-01-05 Anti-arrythmic drugs and cholesterol absorption inhibitors as neuroprotective agents for the treatment of neurodegenerative and autoimmune disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL16614905A IL166149A0 (en) 2005-01-05 2005-01-05 Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity

Publications (1)

Publication Number Publication Date
IL166149A0 true IL166149A0 (en) 2006-01-15

Family

ID=36096777

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16614905A IL166149A0 (en) 2005-01-05 2005-01-05 Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity

Country Status (2)

Country Link
IL (1) IL166149A0 (en)
WO (1) WO2006072957A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
UY29607A1 (en) 2005-06-20 2007-01-31 Astrazeneca Ab CHEMICAL COMPOUNDS
SA06270191B1 (en) 2005-06-22 2010-03-29 استرازينيكا ايه بي Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions
AR057072A1 (en) 2005-06-22 2007-11-14 Astrazeneca Ab CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE, PHARMACEUTICAL FORMULATION AND A COMPOUND PREPARATION PROCESS
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
GB0624757D0 (en) * 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2337037T3 (en) * 2002-03-27 2010-04-20 Glaxosmithkline Llc CERTAIN PHARMACEUTICALLY USEFUL REPLACED AMINOALKYL HETEROYCLES.
MXPA05004811A (en) * 2002-11-06 2005-07-22 Schering Corp Cholesterol absorptions inhibitors for the treatment of autoimmune disorders.

Also Published As

Publication number Publication date
WO2006072957A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
IL188420A0 (en) Methods and compositions with enhanced therapeutic activity
EP2115570A4 (en) Protection agents and privilege modes
EP1850823A4 (en) Hyperbaric oxygen devices and delivery methods
PT2162118T (en) Porous microspheres and their use in therapy
EP1913112A4 (en) Proppant and methods of use
EP1843768A4 (en) Substituted morphinans and methods of their use
HK1103730A1 (en) Pyrrolopyridine derivatives and their use as crth2antagonists
GB0523576D0 (en) Drug composition and its use in therapy
IL190055A0 (en) Quinolines and their therapeutic use
IL191072A0 (en) Therapeutic compositions and methods
SI1828201T1 (en) Macrocyclic quinazoline derivatives and their use as mtki
IL176772A0 (en) Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors
EP1928656A4 (en) Protective composite structures and methods of making protective composite structures
IL182469A0 (en) Combination comprising zd6474 and an antiandrogen
PL377180A1 (en) Application of isoflavones and their derivatives in Mucopolysacharidose treatment
IL177435A0 (en) Expression of plasminogen and microplasminogen in duckweed
EP1733045A4 (en) Design and therapeutic use of adpase enhanced apyrases
IL198721A0 (en) Acat inhibitors and their use in the prevention or treatment of fibrosis
IL166149A0 (en) Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity
GB2438334B (en) Improvements in and relating to blast protection structures
EP1858507A4 (en) Polyphenol coxib combinations and methods
EP1962589A4 (en) Synergistic combinations of norketamine and opioid analgesics
GB0804039D0 (en) Anti-malarial composition comprising artesunate and lumefantrine
IL185575A0 (en) Benzoxazocines and their therapeutic use
ZA200802683B (en) Quinolines and their therapeutic use